Sequent Scientific Ltd. reported consolidated revenue from operations of ₹4.24 billion and a net profit of ₹147.4 million for the September 2025 quarter. The results reflect steady performance in the animal health segment, supported by operational efficiency and strategic market expansion.
Sequent Scientific Ltd. (NSE: SEQUENT) has released its unaudited financial results for the quarter ended September 30, 2025, as per its filing with the National Stock Exchange. The company, a leading player in the animal health pharmaceutical space, delivered consistent growth in both revenue and profitability.
Major takeaways:
- Consolidated revenue from operations stood at ₹4.24 billion, driven by stable demand across key geographies
- Net profit for the quarter reached ₹147.4 million, reflecting improved cost management and margin discipline
- The company continues to focus on expanding its global footprint, particularly in regulated markets
- Operational efficiency and portfolio optimization contributed to the quarter’s profitability
- Management remains optimistic about long-term growth, citing innovation and strategic partnerships as key drivers
These results reinforce Sequent’s position as a resilient mid-cap pharma player with a specialized focus on veterinary therapeutics.
Source: NSE Circular dated November 14, 2025 (Symbol: SEQUENT)